- Home
- MYNZ vs ABVC Comparison
MYNZ vs ABVC Comparison
Compare MYNZ & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYNZ
- ABVC
- Stock Information
- Founded
- MYNZ 2021
- ABVC 2015
- Country
- MYNZ Germany
- ABVC United States
- Employees
- MYNZ N/A
- ABVC N/A
- Industry
- MYNZ Biotechnology: Pharmaceutical Preparations
- ABVC Biotechnology: Pharmaceutical Preparations
- Sector
- MYNZ Health Care
- ABVC Health Care
- Exchange
- MYNZ Nasdaq
- ABVC Nasdaq
- Market Cap
- MYNZ 11.2M
- ABVC 12.8M
- IPO Year
- MYNZ 2021
- ABVC N/A
- Fundamental
- Price
- MYNZ $4.83
- ABVC $0.54
- Analyst Decision
- MYNZ Hold
- ABVC
- Analyst Count
- MYNZ 2
- ABVC 0
- Target Price
- MYNZ N/A
- ABVC N/A
- AVG Volume (30 Days)
- MYNZ 135.3K
- ABVC 150.8K
- Earning Date
- MYNZ 10-21-2024
- ABVC 03-12-2025
- Dividend Yield
- MYNZ N/A
- ABVC N/A
- EPS Growth
- MYNZ N/A
- ABVC N/A
- EPS
- MYNZ N/A
- ABVC N/A
- Revenue
- MYNZ $917,203.00
- ABVC $509,788.00
- Revenue This Year
- MYNZ $21.95
- ABVC N/A
- Revenue Next Year
- MYNZ $30.77
- ABVC N/A
- P/E Ratio
- MYNZ N/A
- ABVC N/A
- Revenue Growth
- MYNZ 16.23
- ABVC N/A
- 52 Week Low
- MYNZ $0.18
- ABVC $0.41
- 52 Week High
- MYNZ $7.95
- ABVC $1.73
- Technical
- Relative Strength Index (RSI)
- MYNZ 53.87
- ABVC 47.67
- Support Level
- MYNZ $3.86
- ABVC $0.50
- Resistance Level
- MYNZ $6.81
- ABVC $0.58
- Average True Range (ATR)
- MYNZ 0.74
- ABVC 0.06
- MACD
- MYNZ -0.09
- ABVC -0.01
- Stochastic Oscillator
- MYNZ 32.88
- ABVC 20.63
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.